HeartBeam Ranked Second Globally in Portable ECG Innovation

HeartBeam has been recognized as a Global IP and Technology Leader in Portable Cardiac Diagnostics by PatentVest's "Total Cardiac Intelligence" report. The medical-technology company ranked second worldwide in 12-lead ECG innovation among 243 firms evaluated, trailing only GE Healthcare in the comprehensive analysis. This recognition underscores HeartBeam's significant progress in developing advanced electrocardiogram solutions for remote cardiac care.

The company's high ranking reflects the maturation of its proprietary synthesis-ECG system, which captures the heart's electrical signals in three noncoplanar dimensions and synthesizes them into a 12-lead ECG. This technological approach represents a substantial advancement in portable cardiac diagnostics, enabling physicians to obtain comprehensive heart data outside traditional clinical settings. The recognition highlights HeartBeam's growing influence in the next generation of cardiac monitoring technology and its strong intellectual property foundation, which includes over 20 issued patents related to technology enablement.

HeartBeam's portable non-invasive recorder is designed to record, store, and transfer a patient's 3-lead electrocardiogram acquired from five electrodes. The device is intended for use by adult patients in either clinical settings or at home, providing flexibility in cardiac monitoring. While the device does not conduct cardiac analysis itself, it can be used with ECG Viewer software systems for manual interpretation of non-life-threatening arrhythmias by physicians or healthcare professionals. For detailed safety information, readers can consult the full Instructions for Use or Clinician Portal Manual.

The company's technological platform represents a significant step forward in cardiac health management. By creating the first-ever cable-free device capable of collecting ECG signals in 3D from three non-coplanar directions and synthesizing them into a 12-lead ECG, HeartBeam is positioned to transform how cardiac conditions are detected and monitored. This innovation allows physicians to identify cardiac health trends and acute conditions while directing patients to appropriate care entirely outside medical facilities.

HeartBeam's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, with the 12-lead ECG synthesis software currently under FDA review. The company's progress in regulatory approvals combined with its strong intellectual property portfolio suggests potential for significant impact on remote cardiac care. The latest news and updates relating to the company are available in the corporate newsroom at https://ibn.fm/BEAT.

This recognition as a global innovation leader in portable ECG technology comes at a time when remote healthcare solutions are increasingly important. The ability to provide comprehensive cardiac monitoring outside traditional medical facilities could significantly improve patient access to cardiac care, reduce healthcare costs, and enable earlier detection of cardiac conditions. As the company continues to advance its technology through the regulatory process, its position as a global leader in portable cardiac diagnostics suggests potential for substantial impact on how cardiac health is managed worldwide.